Scholars Central

Conference abstractPublished 17 Sep 2018

Targeting IL11 to treat fibrotic disorders

Authors: Sebastian Schafer

National Heart Centre Singapore, Singapore; Duke-NUS Medical School, Singapore

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

We have previously shown how mutations in large structural proteins (titin) or modifiers thereof (RBM20) contribute to inherited cardiac diseases such as dilated cardiomyopathy. However, even though these mutations predispose to disease, they are difficult to target therapeutically. One common pathology in many cardiovascular diseases is fibrosis of the heart or kidney, which may be prevented if suitable therapeutic targets can be identified. While TGF-beta is the exemplar target for fibrosis, its inhibition causes overwhelming toxicities and alternative approaches are needed. We modeled fibrosis using fibroblasts outgrown from atrial biopsies from 84 patients. Fibroblasts were stimulated with TGF-beta and the fibrotic response assessed by integrating RNA sequencing with high-content imaging of cell trans-differentiation, Extracellular Matrix (ECM) production and proliferation. This screen prioritized interleukin 11 (IL11) as a potential therapeutic target for fibrosis. Follow-up experiments revealed that IL11 was essential for the pro-fibrotic activity of TGFB1 in fibroblasts. An autocrine loop of IL11 signaling represents a point of signaling convergence for a number of key pro-fibrotic stimuli, including angiotensin II and endothelin 1. IL11 regulates post-transcriptional gene expression in fibrosis and acts through a non-canonical, ERKdependent pathway. In vivo experiments substantiated the pro-fibrotic nature of IL11 and its administration to mice induced severe cardiac and renal dysfunction. We then developed antibodies that neutralize IL11 signaling to inhibit fibrosis and improve organ function. These therapeutic agents may be a promising novel approach to tackle the increasing burden on human health caused by untreatable fibrotic disorders.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical and Experimental Cardiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical and Experimental Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “Sebastian Schafer”